Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01297062 · ClinicalTrials.gov registry record · Phase 1
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT01297062 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 94 participants.
The verdict
NCT01297062, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
Compare the effect of exenatide (therapeutic and supratherapeutic concentrations), moxifloxacin and placebo on the QT interval.
Interventions
- DRUG Moxifloxacin
- DRUG Exenatide
- DRUG Placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01297062
The ClinicalTrials.gov registry entry for NCT01297062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT01297062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01297062 about?
NCT01297062 is a clinical study titled "A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects". Compare the effect of exenatide (therapeutic and supratherapeutic concentrations), moxifloxacin and placebo on the QT interval.
What is the current status of trial NCT01297062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2011-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01297062?
The interventions under investigation include: Moxifloxacin (DRUG), Exenatide (DRUG), Placebo comparator (DRUG).
Who is sponsoring clinical trial NCT01297062?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.